Neil William Aubuchon net worth and biography

Neil Aubuchon Biography and Net Worth

Insider of Viking Therapeutics

Mr. Aubuchon serves as our Chief Commercial Officer and brings more than two decades of biopharmaceutical industry experience spanning leadership roles across global commercial and marketing functions including focus within the cardiometabolic space. Prior to joining Viking, Mr. Aubuchon was the chief commercial officer at AbCellera, where he was responsible for developing the company’s commercial strategy. Prior to AbCellera, he was the global marketing lead for Amgen’s general medicine early portfolio, where he developed the integrated strategy for the company’s non-oncology therapeutic areas and led commercial strategy for more than ten programs, including its cardiometabolic portfolio. Before his time at Amgen, Mr. Aubuchon spent nearly 17 years at Eli Lilly in various commercial roles including, chief marketing officer in Australia, chief marketing officer in Japan, head of strategy and operations for Lilly Bio-Medicines globally, and vice president of Lilly Bio-Medicines in Japan.

What is Neil William Aubuchon's net worth?: The estimated net worth of Neil William Aubuchon is at least $152.79 thousand as of March 10th, 2026. Aubuchon owns 4,475 shares of Viking Therapeutics stock worth more than $152,790 as of March 11th. This net worth estimate does not reflect any other assets that Aubuchon may own. Learn More about Neil William Aubuchon's net worth.
How do I contact Neil William Aubuchon?: The corporate mailing address for Aubuchon and other Viking Therapeutics executives is 12340 EL CAMINO REAL SUITE 250, SAN DIEGO CA, 92130. Viking Therapeutics can also be reached via phone at (858) 704-4660 and via email at [email protected]. Learn More on Neil William Aubuchon's contact information.
Has Neil William Aubuchon been buying or selling shares of Viking Therapeutics?: Over the course of the past ninety days, Neil William Aubuchon has bought $149,912.50 in shares of Viking Therapeutics stock. Most recently, on Tuesday, March 10th, Neil William Aubuchon bought 4,475 shares of Viking Therapeutics stock. The stock was acquired at an average cost of $33.50 per share, with a total value of $149,912.50. Following the completion of the transaction, the insider now directly owns 4,475 shares of the company's stock, valued at $149,912.50. Learn More on Neil William Aubuchon's trading history.
Who are Viking Therapeutics' active insiders?: Viking Therapeutics' insider roster includes Neil Aubuchon (Insider), Matthew Foehr (Director), Brian Lian (CEO), Lawson Macartney (Director), Marianna Mancini (COO), Sarah Rouan (Director), Charles Rowland, Jr. (Director), J. Matthew Singleton (Director), and Greg Zante (CFO). Learn More on Viking Therapeutics' active insiders.
Are insiders buying or selling shares of Viking Therapeutics?: In the last year, Viking Therapeutics insiders bought shares 2 times. They purchased a total of 5,715 shares worth more than $179,858.50. In the last year, insiders at the biotechnology company sold shares 11 times. They sold a total of 511,511 shares worth more than $16,970,187.39. The most recent insider tranaction occured on March, 10th when insider Neil William Aubuchon bought 4,475 shares worth more than $149,912.50. Insiders at Viking Therapeutics own 4.1% of the company. Learn More about insider trades at Viking Therapeutics.
Information on this page was last updated on 3/10/2026.

Neil William Aubuchon Insider Trading History at Viking Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
3/10/2026	Buy	4,475	$33.50	$149,912.50	4,475

Neil William Aubuchon Buying and Selling Activity at Viking Therapeutics

Viking Therapeutics Company Overview

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

Today's Range

Now: $35.78

$33.91

$35.63

50 Day Range

MA: $31.78

$26.29

$35.42

2 Week Range

Now: $35.78

$18.92

$43.15

Volume

2,730,026 shs

Average Volume

3,178,746 shs

Market Capitalization

$4.13 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.75